Table 2.

The different therapeutic combinations with EZH2 inhibitor and the EZH2 targeted genes involved combination therapy

Cancer therapy	Therapeutic method	EZH2 target genes	Cancer types	Refs
Immunotherapy	Anti-CTLA-4	–	Bladder cancer	[38]
	Anti-PD-L1	CD274, IRF1	Hepatocellular carcinoma	[40]
	Anti-PD-1	NLRC5, CIITA	Head and neck cancer	[41]
	Anti-MDSCs	–	Colon cancer	[48]
Chemotherapy	Docetaxel	Nanog, Sox2, CD44	Prostate cancer	[55]
	Etoposide	BRG1, EGFR	Lung cancer	[56, 57]
	Cisplatin	–	Cervical cancer	[58]
		MiR-137	Ovarian cancer	[59]
		–	Osteosarcoma	[60]
	Temozolomide	MDR, MRP, BCRP	Glioblastoma	[61]
	Doxorubicin, Melphalan	ATM	Multiple myeloma	[64]
	Epirubicin, Mitomycin C	P53, ATM, FOXO3	Hepatocellular carcinoma	[65]
Targeted therapy	PARP inhibitor	MAD2L2	Ovarian cancer	[74]
		HOXA9, DAB2IP	Breast cancer	[75]
	HDAC inhibitor	P16, P21, P27, FBXO32	Acute myeloid leukemia	[78]
		–	Lymphomas	[80]
		NKD1, PPP2R2B	Lung cancer	[81]
		P21	Ovarian cancer	[82]
Endocrine therapy	Anti-androgen	PSA, TMPRSS2	Prostate cancer	[85]
		AR	Prostate cancer	[86, 87]
	Anti-estrogen	GREB1	Breast cancer	[90]